We use cookies for a better user experience. Read our Privacy Policy

I Agree

Biotherapeutics Cell Line Development Market

Biotherapeutics Cell Line Development Market (Process: Transfection & Selection and Single Cell Cloning; and CLD Option: In-house, Outsourced, Do-It-Yourself, and Hybrid) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Research and Development Activities to Redefine Next-generation Biotherapeutics Cell Line Development

The protein pharmaceutical space has gradually matured into a multibillion-dollar industry over the past couple of decades. However, identifying the ideal bio-therapeutic development cell lines has posed as a major barrier in the manufacturing process. Biotherapeutic cell line development has reached new frontiers, owing to considerable genomic research and development activities. In addition, existing as well as emerging technologies in the biotherapeutics cell line development have played an integral role in pushing cell engineering toward new frontiers. Over the past couple of decades, considerable work has been put in toward optimization of codons and construction of vectors due to which, biotherapeutics cell line development has garnered noteworthy attention.

Regulatory changes, introduction of new technologies, and advent of an array of innovative concepts have played a key role in influencing the overall growth of the global biotherapeutics cell line development market over the past few years– a trend that is expected to continue during the forecast period. Over the past few decades, academic and commercial scientists have largely focused on addressing the shortcomings of initial formulations of biotherapeutics cell lines. Several companies operating in the current biotherapeutics cell line development market landscape are introducing new variants of cell line development solutions to cater to industrial requirements.

At the back of these factors, along with consistent rise in the number of investments, the global biotherapeutics cell line development market is expected to reach ~US$ 224 Mn by 2030. Apart from these factors, the growing support offered by government bodies around the world to promote biotechnology and the pharmaceutical industry is another factor that is expected to set the tone for the development of the global biotherapeutics cell line development market during the assessment period.

Biotherapeutic Cell Line Development Market Infographic

To know the scope of our report Get a Sample on Biotherapeutics Cell Line Development Market

CHO Cells Likely to Remain Integral for Biological Therapeutics

As the protein pharmaceutical industry continues to take giant strides in the forward direction, it has a direct impact on the growth of the biotherapeutics cell line development market. For the longest time, Chinese Hamster Ovary (CHO) cells have remained the most popular expression system for biotherapeutics cell line development, as it is accepted by the FDA and thereby, makes the regulatory approval an easy process. In addition, these biotherapeutics cell lines have the ability to grow in suspension, resistant to viral infection, and are relatively easier to work with. These factors are expected to play a key role in the progress of the global biotherapeutics cell line development market during the assessment period.

However, at present, market players are increasingly focusing on streamlining the process of segregating high-producing protein secretors from low-producing protein secretors, which are highly tedious and time-consuming as over thousands of clones are screened in a period of few weeks. However, the onset of the multi-open reading frame (ORF) constructs in cells could possibly lead to a compromise, fragmented DNA being integrated into the genome in place of the requisite sequence. Market players operating in the current market for biotherapeutics cell line development are increasingly focusing on streamlining segregation processes to fast-track cell line development. At present, the pursuit of novel biopharmaceutical agents continues to remain one of the most critical challenges in the pharmaceutical research and drug development sphere.

Biotherapeutic cell line development plays a critical role in these research activities. However, at present, researchers and scientists are largely focusing on addressing the numerous challenges involved with cell lines such as quality, robustness, productivity, scaling-up, etc.

Biotherapeutic Cell Line Development Market Segmentation

Get a glimpse of the in-depth analysis through our Report Brochure

Mergers, Collaboration, and Entry of New Solutions Provide Impetus for Market Growth

Over the past decade, a number of organizations involved in the biotherapeutics cell line development market are highly inclined toward the development of new technologies that enable the production and manufacturing of various innovative biopharmaceuticals, including gene therapy vectors and complex therapeutic cell lines. In addition, several market participants are also roping in considerable efforts to fast-track screening and biotherapeutics cell line development to develop high-end biopharmaceutical solutions, including complex fusion proteins, viral particles, and largely glycosylated plasma proteins.

Several market players are launching new workflow models to optimize the identification process of top clones for complex antibody therapeutics. For instance, in March 2020, Berkeley Light launched the cell line development 2.0 workflow to identify the most ideal clones for complex antibody therapeutics. The newly launched Opto CLD 2.0 workflow allows the measurement of antibody production in over thousands of clones by utilizing the company’s assays. With a similar aim to increase lab productivity and minimize the timeline of biotherapeutics cell line development, in June 2019, Sartorius Stedim Biotech launched a new generation cell culture micro-bioreactor system.

Market Players Scramble to Find New Solutions to Stop COVID-19 Transmission

The COVID-19 pandemic is currently playing a huge role in derailing the world economy, as industries and businesses around the world continue to remain shut due to social distancing norms and lockdowns enforced by governments. While several industrial sectors are witnessing minimal activity during the COVID-19 event, the pharmaceutical sector is currently burdened with the demand for effective solutions and products to combat the COVID-19 infection. Several players operating in the current biotherapeutics cell line development market are investing in research and development activities to combat the COVID-19 virus. Market players are expected to look beyond the conventional means of antibody-drug manufacturing and discover novel ways to enhance productivity. Several market players are currently collaborating with scientists to discover potential solutions to prevent the spread of the COVID-19 infection. While the market is likely to witness steady growth in 2020 due to the COVID-19 event, all eyes will be on research and development activities.

Analysts’ Viewpoint

The global biotherapeutics cell line development market is expected to grow at a CAGR of ~7% during the forecast period. The market growth will be largely driven by research and development activities due to which, new solutions and technologies have gradually entered the market. Developments in the pharmaceutical sector will ideally focus on enhancing lab productivity and minimizing the overall time taken for biotherapeutics cell line development. While the COVID-19 pandemic will disrupt operations and workflow models across the biotherapeutics cell line development market, it presents an opportunity for market participants to focus on research activities that explore the possibilities of non-conventional antibody manufacturing techniques.  

Biotherapeutics Cell Line Development Market: Overview

  • Biotherapeutics need cell lines for different activities such as new product development and research. The cell line development involves primary cells taken directly from an animal or living body, without any significant manipulation; the cells that have been transformed or partially transformed; or the cells continually derived from a culture with stem-like properties for biotherapeutics.
  • Transfection is the process of introducing foreign DNA into the cells by using either the physical (electroporation) or chemical (cationic lipid or calcium phosphate reagents) method
  • Single cell cloning is essentially a process of generation of single-cell clones from an original ‘multi-clonal’ population; however, this population is separated from the rest in order to create pure, clonal population that is genetically identical
  • Rise in the demand for biotherapeutics led by the recent launches of biopharmaceutical drugs is a major factor driving the global biotherapeutics cell line development market
  • For instance, the U.S. FDA approved total 12 biologics and 34 small-molecule drugs in 2017, while the number increased to 17 biologics and 42 small-molecule drugs in 2018
  • Increase in geriatric population, rise in the prevalence of diseases, and development of advanced technologies to meet the rising demand for monoclonal antibodies are some of the major factors augmenting the global biotherapeutics cell line development market
  • Moreover, government initiatives to boost the biotechnology & pharmaceutical sector are also fuelling the global biotherapeutics cell line development market

Market Segmentation: Global Biotherapeutics Cell Line Development Market

  • Based on process, the global biotherapeutics cell line development market has been bifurcated into transfection & selection and single cell cloning
  • The single cell cloning segment has been sub-divided into manual LDC, FACs, ClonePix, and others
  • In terms of CLD option, the global biotherapeutics cell line development market has been divided into in-house, outsourced, Do-It-Yourself, and hybrid
  • Each of the segments of the global biotherapeutics cell line development market has been analyzed in detail for recent trends and developments, drivers, restraints, opportunities, and useful insights. The report on the global biotherapeutics cell line development market provides current and future revenues (US$ Mn) for each of these segments for the period from 2018 to 2030, considering 2019 as the base year. The compounded annual growth rate (% CAGR) has been provided for each segment of the market from 2020 to 2030, along with market size estimations.

Regional Overview: Biotherapeutics Cell Line Development Market

  • In terms of region, the global biotherapeutics cell line development market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The markets in these regions have been further divided into major countries and sub-regions.
  • North America dominated the global biotherapeutics cell line development market in 2019 and the trend is expected to continue during the forecast period
  • Asia Pacific is likely to be a highly lucrative market for biotherapeutics cell line development during the forecast period
  • The biotherapeutics cell line development market size in terms of revenue (US$ Mn) for different regions and their major countries have been provided in the report for the period from 2018 to 2030, along with their CAGRs for the period from 2020 to 2030
  • The study also offers a list of recommendations, highlights, and useful insights of the global market, which would help new companies willing to enter the market and the existing companies gain higher market share. It would also help them in the decision-making process.

Major Players

  • The report on the global biotherapeutics cell line development market concludes with the company profiles section, which includes key information about major players operating in the market
  • Key players analyzed in the report on the global biotherapeutics cell line development market are 
    • Merck KGaA
    • Becton
    • Dickinson and Company (BD)
    • Danaher Corporation
    • Boehringer Ingelheim Group
    • Thermo Fisher Scientific, Inc
    • Lonza Group Ltd.
    • Probiogen AG
    • Solentim Ltd.
    • Selexis SA
    • Sysmex Corporation.
  • Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Biotherapeutics Cell Line Development Market – Segmentation

TMR’s study on the global biotherapeutics cell line development market includes information divided into three sections: process, CLD option, and region. Changing industry trends and other crucial market dynamics associated with these sections of the global biotherapeutics cell line development market have been discussed in detail.

Process

Transfection & Selection

Single Cell Cloning

  • Manual LDC
  • FACs
  • ClonePix
  • Others

CLD Option

In-house

Outsource

Do-It-Yourself

Hybrid

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Biotherapeutics Cell Line Development Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of biotherapeutics cell line development market?

Biotherapeutics cell line development market is expected to reach ~US$ 224 Mn by 2030

What is the anticipated CAGR of the biotherapeutics cell line development market in the forecast period?

Biotherapeutics cell line development market is expected to grow at a CAGR of ~7% during 2020 - 2030

What are the key driving factors for the growth of the biotherapeutics cell line development market?

Biotherapeutics cell line development market is driven by rise in the demand for biotherapeutics led by the recent launches of biopharmaceutical drugs

Which region is expected to project the highest market share in the global biotherapeutics cell line development market?

North America accounted for a major share of the global biotherapeutics cell line development market and the trend is expected to continue during the forecast period

Who are the key players in the biotherapeutics cell line development market?

Key players in the global biotherapeutics cell line development market include Merck KGaA, Becton, Dickinson and Company (BD), Danaher Corporation

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Biotherapeutics Cell Line Development Market

4. Market Overview

    4.1. Introduction

        4.1.1. Process Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Biotherapeutics Cell Line Development Market Analysis and Forecast, 2018–2030

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Key Mergers & Acquisitions 

    5.2. Overview of Cell Line Development Process for Biotherapeutics 

    5.3. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

6. Global Biotherapeutics Cell Line Development Market Analysis and Forecast, by Process 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Process, 2018–2030

        6.3.1. Transfection & Selection

        6.3.2. Single Cell Cloning

            6.3.2.1. Manual LDC

            6.3.2.2. FACs

            6.3.2.3. ClonePix

            6.3.2.4. Others

    6.4. Market Attractiveness, by Process, 2020-2030

7. Global Biotherapeutics Cell Line Development Market Analysis and Forecast, by  CLD Option 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by  CLD Option, 2018–2030

        7.3.1. In-house

        7.3.2. Outsource

        7.3.3. Do-It-Yourself

        7.3.4. Hybrid

    7.4. Market Attractiveness, by CLD Option, 2020-2030

8. Global Biotherapeutics Cell Line Development Market Analysis and Forecast, by  Region

    8.1. Key Findings

    8.2. Market Value Forecast, by  Region

        8.2.1. North America 

        8.2.2. Europe 

        8.2.3. Asia Pacific 

        8.2.4. Latin America 

        8.2.5. Middle East & Africa 

    8.3. Market Attractiveness, by Country/Region, 2020-2030

9. North America Biotherapeutics Cell Line Development Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by  Process, 2018–2030

        9.2.1. Transfection & Selection

        9.2.2. Single Cell Cloning

            9.2.2.1. Manual LDC

            9.2.2.2. FACs

            9.2.2.3. ClonePix

            9.2.2.4. Others

    9.3. Market Value Forecast, by  CLD Option, 2018–2030

        9.3.1. In-house

        9.3.2. Outsource

        9.3.3. Do-It-Yourself

        9.3.4. Hybrid

    9.4. Market Value Forecast, by  Country, 2018–2030

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis, 2020-2030

        9.5.1. By Process 

        9.5.2. By CLD Option 

        9.5.3. By Country

10. Europe Biotherapeutics Cell Line Development Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by  Process, 2018–2030

        10.2.1. Transfection & Selection

        10.2.2. Single Cell Cloning

            10.2.2.1. Manual LDC

            10.2.2.2. FACs

            10.2.2.3. ClonePix

            10.2.2.4. Others

    10.3. Market Value Forecast, by  CLD Option, 2018–2030

        10.3.1. In-house

        10.3.2. Outsource

        10.3.3. Do-It-Yourself

        10.3.4. Hybrid

    10.4. Market Value Forecast, by  Country/Sub-region, 2018–2030

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Market Attractiveness Analysis, 2020-2030

        10.5.1. By Process 

        10.5.2. By CLD Option 

        10.5.3. By Country/Sub-region

11. Asia Pacific Biotherapeutics Cell Line Development Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by  Process, 2018–2030

        11.2.1. Transfection & Selection

        11.2.2. Single Cell Cloning

            11.2.2.1. Manual LDC

            11.2.2.2. FACs

            11.2.2.3. ClonePix

            11.2.2.4. Others

    11.3. Market Value Forecast, by  CLD Option, 2018–2030

        11.3.1. In-house

        11.3.2. Outsource

        11.3.3. Do-It-Yourself

        11.3.4. Hybrid

    11.4. Market Value Forecast, by  Country/Sub-region, 2018–2030

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Market Attractiveness Analysis, 2020-2030

        11.5.1. By Process 

        11.5.2. By CLD Option 

        11.5.3. By Country/Sub-region

12. Latin America Biotherapeutics Cell Line Development Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by  Process, 2018–2030

        12.2.1. Transfection & Selection

        12.2.2. Single Cell Cloning

            12.2.2.1. Manual LDC

            12.2.2.2. FACs

            12.2.2.3. ClonePix

            12.2.2.4. Others

    12.3. Market Value Forecast, by  CLD Option, 2018–2030

        12.3.1. In-house

        12.3.2. Outsource

        12.3.3. Do-It-Yourself

        12.3.4. Hybrid

    12.4. Market Value Forecast, by  Country/Sub-region, 2018–2030

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Market Attractiveness Analysis, 2020-2030

        12.5.1. By Process 

        12.5.2. By CLD Option 

        12.5.3. By Country/Sub-region

13. Middle East & Africa Biotherapeutics Cell Line Development Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by  Process, 2018–2030

        13.2.1. Transfection & Selection

        13.2.2. Single Cell Cloning

            13.2.2.1. Manual LDC

            13.2.2.2. FACs

            13.2.2.3. ClonePix

            13.2.2.4. Others

    13.3. Market Value Forecast, by  CLD Option, 2018–2030

        13.3.1. In-house

        13.3.2. Outsource

        13.3.3. Do-It-Yourself

        13.3.4. Hybrid

    13.4. Market Value Forecast, by  Country/Sub-region, 2018–2030

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Market Attractiveness Analysis, 2020-2030

        13.5.1. By Process 

        13.5.2. By CLD Option 

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player – Competition Matrix (By Tier and Size of companies)

    14.2. Market Share Analysis, by Company (2019)

    14.3. Company Profiles

        14.3.1. Merck KGaA

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Company Financials

            14.3.1.3. Growth Strategies

            14.3.1.4. SWOT Analysis

        14.3.2. Becton, Dickinson and Company (BD)

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Company Financials

            14.3.2.3. Growth Strategies

            14.3.2.4. SWOT Analysis

        14.3.3. Danaher Corporation

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Company Financials

            14.3.3.3. Growth Strategies

            14.3.3.4. SWOT Analysis

        14.3.4. Boehringer Ingelheim Group 

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Company Financials

            14.3.4.3. Growth Strategies

            14.3.4.4. SWOT Analysis

        14.3.5. Thermo Fisher Scientific Inc.

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Company Financials

            14.3.5.3. Growth Strategies

            14.3.5.4. SWOT Analysis

        14.3.6. Lonza Group Ltd.

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Company Financials

            14.3.6.3. Growth Strategies

            14.3.6.4. SWOT Analysis

        14.3.7. ProBioGen AG

            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.7.2. Company Financials

            14.3.7.3. Growth Strategies

            14.3.7.4. SWOT Analysis

        14.3.8. Solentim Ltd.

            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.8.2. Company Financials

            14.3.8.3. Growth Strategies

            14.3.8.4. SWOT Analysis

        14.3.9. Selexis SA

            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.9.2. Company Financials

            14.3.9.3. Growth Strategies

            14.3.9.4. SWOT Analysis

        14.3.10. Sysmex Corporation

            14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.10.2. Company Financials

            14.3.10.3. Growth Strategies

            14.3.10.4. SWOT Analysis

List of Tables

Table 01: Key Mergers, Acquisitions, and Strategic Partnership

Table 02: Global Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by Process, 2018–2030

Table 03: Global Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by Single Cell Cloning, 2018–2030

Table 04: Global Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by CLD Option, 2018–2030

Table 05: Global Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 06: North America Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by Country, 2018–2030

Table 07: North America Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by Process, 2018–2030

Table 08: North America Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by Single Cell Cloning, 2018–2030

Table 09: North America Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by CLD Option, 2018–2030

Table 10: Europe Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 11: Europe Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by Process, 2018–2030

Table 12: Europe Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by Single Cell Cloning, 2018–2030

Table 13: Europe Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by CLD Option, 2018–2030

Table 14: Asia Pacific Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 15: Asia Pacific Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by Process, 2018–2030

Table 16: Asia Pacific Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by Single Cell Cloning, 2018–2030

Table 17: Asia Pacific Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by CLD Option, 2018–2030

Table 18: Latin America Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 19: Latin America Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by Process, 2018–2030

Table 20: Latin America Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by Single Cell Cloning, 2018–2030

Table 21: Latin America Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by CLD Option, 2018–2030

Table 22: Middle East & Africa Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 23: Middle East & Africa Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by Process, 2018–2030

Table 24: Middle East & Africa Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by Single Cell Cloning, 2018–2030

Table 25: Middle East & Africa Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, by CLD Option, 2018–2030

List of Figures

Figure 01: Global Biotherapeutics Cell Line Development Market Value (US$ Mn) and Distribution, by Region, 2019 and 2030

Figure 02: Global Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast, 2018–2030

Figure 03: Global Biotherapeutics Cell Line Development Market Value Share, by Process, 2019

Figure 04: Global Biotherapeutics Cell Line Development Market Value Share, by CLD Option, 2019

Figure 05: Global Biotherapeutics Cell Line Development Market Value Share, by Single Cell Cloning, 2019

Figure 06: Global Biotherapeutics Cell Line Development Market Value Share, by Region, 2019

Figure 07: Biotherapeutics Workflow

Figure 08: Global Biotherapeutics Cell Line Development Market Value Share Analysis, by Process, 2019 and 2030

Figure 09: Global Biotherapeutics Cell Line Development Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Transfection & Selection, 2018-2030

Figure 10: Global Biotherapeutics Cell Line Development Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Single Cell Cloning, 2018-2030

Figure 11: Global Biotherapeutics Cell Line Development Market Attractiveness Analysis, by Process, 2020–2030

Figure 12: Global Biotherapeutics Cell Line Development Market Value Share Analysis, by CLD Option, 2019 and 2030

Figure 13: Global Biotherapeutics Cell Line Development Market Revenue (US$ Mn) and Y-o-Y Growth (%), by In-house, 2018-2030

Figure 14: Global Biotherapeutics Cell Line Development Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Outsource, 2018-2030

Figure 15: Global Biotherapeutics Cell Line Development Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Do-It-Yourself, 2018-2030

Figure 16: Global Biotherapeutics Cell Line Development Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hybrid, 2018-2030

Figure 17: Global Biotherapeutics Cell Line Development Market Attractiveness Analysis, by CLD Option, 2020-2030

Figure 18: Global Biotherapeutics Cell Line Development Market Value Share, by Region, 2019 and 2030

Figure 19: Global Biotherapeutics Cell Line Development Market Attractiveness, by Region, 2020–2030

Figure 20: North America Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2018–2030

Figure 21: North America Biotherapeutics Cell Line Development Market Value Share, by Country, 2019 and 2030

Figure 22: North America Biotherapeutics Cell Line Development Market Attractiveness, by Country, 2020–2030

Figure 23: North America Biotherapeutics Cell Line Development Market Value Share, by Process, 2019 and 2030

Figure 24: North America Biotherapeutics Cell Line Development Market Attractiveness, by Process, 2020–2030

Figure 25: North America Biotherapeutics Cell Line Development Market Value Share, by CLD Option, 2019 and 2030

Figure 26: North America Biotherapeutics Cell Line Development Market Attractiveness, by CLD Option, 2020–2030

Figure 27: Europe Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2018–2030

Figure 28: Europe Biotherapeutics Cell Line Development Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 29: Europe Biotherapeutics Cell Line Development Market Attractiveness Analysis, by Country/sub-region, 2020–2030

Figure 30: Europe Biotherapeutics Cell Line Development Market Value Share, by Process, 2019 and 2030

Figure 31: Europe Biotherapeutics Cell Line Development Market Attractiveness, by Process, 2020–2030

Figure 32: Europe Biotherapeutics Cell Line Development Market Value Share, by CLD Option, 2019 and 2030

Figure 33: Europe Biotherapeutics Cell Line Development Market Attractiveness, by CLD Option, 2020–2030

Figure 34: Asia Pacific Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2018–2030

Figure 35: Asia Pacific Biotherapeutics Cell Line Development Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 36: Asia Pacific Biotherapeutics Cell Line Development Market Attractiveness Analysis, by Country/sub-region,

Figure 37: Asia Pacific Biotherapeutics Cell Line Development Market Value Share, by Process, 2019 and 2030

Figure 38: Asia Pacific Biotherapeutics Cell Line Development Market Attractiveness, by Process, 2020–2030

Figure 39: Asia Pacific Biotherapeutics Cell Line Development Market Value Share, by CLD Option, 2019 and 2030

Figure 40: Asia Pacific Biotherapeutics Cell Line Development Market Attractiveness, by CLD Option, 2020–2030

Figure 41: Latin America Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2018–2030

Figure 42: Latin America Biotherapeutics Cell Line Development Market Value Share, by Country/Sub-region, 2019 and 2030

Figure 43: Latin America Biotherapeutics Cell Line Development Market Attractiveness, by Country/sub-region, 2020–2030

Figure 44: Latin America Biotherapeutics Cell Line Development Market Value Share, by Process, 2019 and 2030

Figure 45: Latin America Biotherapeutics Cell Line Development Market Attractiveness, by Process, 2020–2030

Figure 46: Latin America Biotherapeutics Cell Line Development Market Value Share, by CLD Option, 2019 and 2030

Figure 47: Latin America Biotherapeutics Cell Line Development Market Attractiveness, by CLD Option, 2020–2030

Figure 48: Middle East & Africa Biotherapeutics Cell Line Development Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2018–2030

Figure 49: Middle East & Africa Biotherapeutics Cell Line Development Market Value Share, by Country/Sub-region, 2019 and 2030

Figure 50: Middle East & Africa Biotherapeutics Cell Line Development Market Attractiveness, by Country/sub-region, 2020–2030

Figure 51: Middle East & Africa Biotherapeutics Cell Line Development Market Value Share, by Process, 2019 and 2030

Figure 52: Middle East & Africa Biotherapeutics Cell Line Development Market Attractiveness, by Process, 2020–2030

Figure 53: Middle East & Africa Biotherapeutics Cell Line Development Market Value Share, by CLD Option, 2019 and 2030

Figure 54: Middle East & Africa Biotherapeutics Cell Line Development Market Attractiveness, by CLD Option, 2020–2030

Figure 55: Market Position/Ranking Analysis, 2018, by Tier and Size of the Company 

Figure 56: Merck KGaA, Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019

Figure 57: Merck KGaA, Breakdown of Net Sales (%), by Geography, 2019

Figure 58: Merck KGaA, Breakdown of Net Sales (%), by Business Segment, 2019

Figure 59: Merck KGaA, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2019

Figure 60: BD Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019

Figure 61: BD Breakdown of Net Sales (%), by Region/Country, 2019

Figure 62: BD Revenue Breakdown of Net Sales (%), by Life Sciences Segment, 2019

Figure 63: BD R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 64: Danaher Corporation, Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019

Figure 65: Danaher Corporation, Breakdown of Net Sales (%), by Geography, 2019

Figure 66: Danaher Corporation, Breakdown of Net Sales (%), by Business Segment, 2019

Figure 67: Danaher Corporation, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2019

Figure 68: Boehringer Ingelheim Group, Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019

Figure 69: Boehringer Ingelheim Group, Breakdown of Net Sales (%), by Geography, 2019

Figure 70: Boehringer Ingelheim Group, Breakdown of Net Sales (%), by Business Segment, 2019

Figure 71: Boehringer Ingelheim Group, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2019

Figure 72: Thermo Fisher Scientific Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019

Figure 73: Thermo Fisher Scientific Inc., Breakdown of Net Sales (%), by Geography, 2019

Figure 74: Thermo Fisher Scientific Inc., Breakdown of Net Sales (%), by Business Segment, 2019

Figure 75: Thermo Fisher Scientific Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2019

Figure 76: Lonza Group Ltd., Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019

Figure 77: Lonza Group Ltd., Breakdown of Net Sales (%), by Geography, 2019

Figure 78: Lonza Group Ltd., Breakdown of Net Sales (%), by Business Segment, 2019

Figure 79: Lonza Group Ltd., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2019

Figure 80: Sysmex Corporation, Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019

Figure 81: Sysmex Corporation, Breakdown of Net Sales (%), by Geography, 2019

Figure 82: Sysmex Corporation, Breakdown of Net Sales (%), by Business Segment, 2019

Figure 83: Sysmex Corporation, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2019

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

844

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved